LMU Munich and ExpreS2ion Biotechnologies Enter a Licensing Agreement
News Feb 24, 2015
ExpreS2ion Biotechnologies has announced the signature of a research license agreement to provide the Gene Center at Ludwig-Maximilians-Universität München with access to its Drosophila Schneider-2 cell-based technology platform - ExpreS2 - for recombinant protein production.
The stable, non-lytic protein expression platform, which is fully cGMP compatible, will complement the existing capabilities in protein expression at the Gene Center. The platform will be used to address expression of complex and “challenging” proteins, including antibody fragments and other proteins.
This license fits with ExpreS2ion Biotechnologies’ vision of making its protein expression system available to top academic centers globally, as one of the standard protein production platforms for research and development in the areas of immunotherapy and therapeutic proteins.
Dr. Charlotte Dyring, CEO of ExpreS2ion Biotechnologies, said: “We are excited to sign this license agreement with the Gene Center at Ludwig-Maximilians-Universität München, a center of excellence for research into genome maintenance and the regulation of gene expression at all levels. The ExpreS2 protein expression system can respond effectively to the high demands in protein quality and quantity of structural biology projects, and it enables successful production of antibodies and antibody fragments that might fail to express in alternative systems. The Gene Center has been testing the ExpreS2 system for protein production, with very satisfying results”.
Professor Dr. Karl-Peter Hopfner, Professor at the Gene Center at Ludwig-Maximilians-Universität München commented: “We want to understand the molecular and structural mechanisms how the cellular DNA repair and antiviral RNA sensing protein machineries detect, signal and repair or remove malignant nucleic acids such as damaged DNA and viral RNA. The ExpreS2 system complements our tool-box of protein expression systems successfully, allowing us to generate the proteins and antibody-based tools we require, to advance our research”.